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Platelet activity is critical in coronary artery disease patients
to prevent acute thrombotic complications (1). Indeed, an
extensive literature has clearly demonstrated that the level
of platelet reactivity (PR) inhibition correlated with the
clinical outcome including cardiovascular death, myocardial
infarction, and early stent thrombosis in patients under-
going percutaneous coronary intervention (PCI). This is
particularly true for thienopyridines and P2Y12–adenosine
diphosphate (ADP) receptor blockade (2). In fact, this
strong relationship seems to be valid for prasugrel (3).
These ﬁndings are in line with the fact that prasugrel only
differs from clopidogrel by a faster and more efﬁcient bio-
activation scheme because the 2 drugs share similar active
metabolites and similar mechanism of action (4).
In recent years, several investigations aimed at deter-
mining the mechanisms of high on-treatment PR (HTPR)See page 505in patients treated with clopidogrel (5). They conﬁrmed that
HTPR is multifactorial, resulting from several mechanisms
including genetic, cellular, and patients-related factors,
which could act alone or in combination.
Particular attention was drawn to the 2* alleles of
CYP2C19, which is involved in clopidogrel metabolism.
In fact, this enzyme participates in both steps of the clopi-
dogrel bioactivation process. This frequent loss of function
alleles was shown to reduce clopidogrel active metabolite
generation, increase the prevalence of HTPR, and to be
associated with ischemic recurrences. Following these ﬁnd-
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paper to disclose.activity could interfere with clopidogrel active metabolite
generation. It is particularly the case with proton pump
inhibitors. However, although a signiﬁcant interaction
emerged between CYP2C19-metabolized proton pump in-
hibitor and clopidogrel, no clinical impact of this biological
interaction could be identiﬁed (6).
In fact, although a large number of factors have been
identiﬁed in the quest for the mechanisms involved in PR
variability with clopidogrel, only a few of them were shown
to have a clinical impact.
Tobacco is a major clinical risk factor for coronary artery
disease. Cigarette smoke is composed of a high number of
toxic components that participate in the initiation and
progression of coronary artery disease. It includes toxins
responsible for vasomotor dysfunction; increased lipid per-
oxidation, adhesion and inﬂammation molecules, smooth
muscle cell proliferation, prothrombotic; and decreased
ﬁbrinolytic factors and leukocytes and platelet activation (7).
All these factors, related to patient environment, contribute
to chronic disease progression and to acute complications
including acute coronary syndromes (ACS). However,
despite all these deleterious effects of cigarette smoking,
a “smoking paradox” has been recently suggested. Indeed
retrospective analyses of major trials observed that smokers
with ACS derived a greater clinical beneﬁt from clopidogrel
compared with nonsmokers. Accordingly, a retrospective
analysis of the CHARISMA (Clopidogrel for High Athe-
rothrombotic Risk and Ischemic Stabilization, Management
and Avoidance) trial suggested a signiﬁcant beneﬁt of clo-
pidogrel in smokers, whereas there was no beneﬁt of clopi-
dogrel in nonsmokers (8). Such interaction between cigarette
smoking and ischemic events in coronary artery disease pa-
tients receiving clopidogrel therapy suggested a pharmaco-
logical interaction.
The study by Gurbel et al. (9), in this issue of the Journal,
aimed at determining whether this suspected smoker’s
paradox has a biological basis. In fact, previous investigations
of the relationship between cigarette smoking and PR in
clopidogrel-treated patients yielded controversial results
(10). Gurbel et al. (9), to better delineate this relationship,
performed a very well designed pharmacodynamic study.
They evaluated the biological efﬁcacy of clopidogrel and of
the new and more potent P2Y12-ADP receptor antagonist,
prasugrel, in smokers and nonsmokers using platelets assays
and active metabolite concentrations measurements because
both are prodrugs. This study included stable coronary artery
disease patients on aspirin therapy.
Although the study fell short of its primary endpoint,
demonstrating only a trend toward a lower “device reported
inhibition of platelet aggregation” in smokers compared with
nonsmokers, the other endpoints clearly pointed to a greater
biological efﬁcacy of clopidogrel in smokers compared with
nonsmokers. The potential effect of cigarette smoking
was particularly signiﬁcant when evaluating PR using the
vasodilator-stimulated phosphoprotein (VASP) index or
the P2Y12 reaction units (PRU), which are both well-
Bonello et al. JACC Vol. 62, No. 6, 2013
Environment, Diseases, and Drugs August 6, 2013:513–5
514validated measures of P2Y12-ADP receptor blockade. Both
tests have been used to reliably predict clinical outcome in
patients undergoing PCI while being treated with clopi-
dogrel (2). Regarding prasugrel, the more potent third-
generation thienopyridine, the authors observed no impact
of smoking status on either platelet assays or PR measure-
ment (9). These ﬁndings are in line with those of the platelet
substudy of the TRITON-TIMI 38 trial (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel-Thrombolysis in Myo-
cardial Infarction 38) or other recent observational
studies demonstrating the high potency of prasugrel and the
fact that most factors associated with HTPR in clopidogrel-
treated patients did not affect PR by prasugrel (3,11). Of
interest, Gurbel et al. (9) further observed that such
a difference in clopidogrel biological efﬁcacy between
smokers and nonsmokers is related to a higher activity of
a cytochrome involved in clopidogrel biotransformation into
its active metabolite CYP1A2. These results validate
a possible explanation for a smoker’s paradox suggested by
recent retrospective studies. However, the complexity of the
studied interactions questions the reliability of the ﬁndings.
First, consistent with the study by Gurbel et al. (9), the role
of CYP1A2 is critical. Park et al. (12) observed that PR was
affected only in those smokers carrying the cytochrome P450
CYP1A2 (163C>A) genotype. Although the methodology
of the present study, and in particular the assessment of
active metabolites, is strong, the interactions between envi-
ronment, disease, drug, and genetics are complex and dif-
ﬁcult to adequately assess. For example, a global evaluation
of platelet activity and thrombotic activity is lacking.
Because cigarette smoking is associated with increased
baseline platelet activity, the overall impact remains to
be determined because Gurbel et al. (9) only evaluated the
P2Y12-ADP receptor pathway.
Overall, these ﬁndings are of great clinical interest. First,
they conﬁrm that clopidogrel is a mild antiplatelet agent
whose biological efﬁcacy is highly variable and inﬂuenced by
both endogenous and exogenous factors (5). Although
several factors were shown to inﬂuence its biological efﬁcacy,
overall few were proven to alter outcome. This is probably
because of the complex interactions between some of these
factors and outcome but also because most of them have
a relatively small biological impact.
In the case of cigarette smoking, the interesting ﬁndings
by Gurbel et al. (9) raise several questions. In fact, thanks to
its positive effect on PR in clopidogrel-treated patients,
could cigarette smoke improve early outcome by reducing
the risk of early stent thrombosis? This question is of great
importance, in particular during the early days of myocardial
infarction when cardiologists advise coronary artery disease
patients to stop cigarette smoking to improve their long-
term outcome. Should we delay having ACS patients
undergoing PCI stop smoking?
Of course this is not the case to date. First, we lack
prospective data that would support the clinical impact ofthese biological ﬁndings. In addition, the hypothesis of a
smoker’s paradox based on retrospective analysis requires
prospective validation. In fact, compared with the data from
the CHARISMA analysis, an analysis of the PLATO
(Platelet Inhibition and Patient Outcomes) trial observed in
patients admitted for ACS, habitual smoking was associated
with a greater risk of subsequent stent thrombosis (13).
Furthermore, the recent literature suggests no link between
PR and ischemic event occurrence in medically managed
ACS patients, thus questioning the clinical relevance of the
results (14). Second cigarette smoking also affects numerous
negative processes involved in atherothrombosis and in
particular increased platelet activity and prothrombotic state
(7). These negative effects are likely to negatively affect the
outcome.
Overall, an interesting point raised by the present study is
the largely understudied impact of the environment on drug
efﬁcacy. With the increasing means at our disposal to
investigate drugs, we will surely be able to develop models
that will help us to better delineate their effects in a partic-
ular patient and environment. At a time when progress is
slowing in the treatment of cardiovascular disease, thanks to
the tremendous decrease in adverse events, the ability to
tailor therapy should be one strong means to further improve
patient outcome.Reprint requests and correspondence: Dr. Laurent Bonello,
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